Media
Videos
Branches
Novartis
Key Trials
8 trials shown
Novartis
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
Study CDFV890G12101 is an open-label, phase 1b, multicenter study with a randomized two-dose optimization part, and a dose expansion part consisting of two groups evaluating DFV890
- Study number:
- NCT05552469
- Cohorts:
- 1
- Study phase:
- 1
- Overall status:
- Not yet recruiting
- Study type:
- Targeted therapy
Novartis
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.
- Study number:
- NCT05358249
- Cohorts:
- 3
- Study phase:
- 1, 2
- Overall status:
- Recruiting
- Study type:
- Targeted therapy, Biomarker
Novartis
PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma
This is a Phase II study to determine the efficacy and safety of PHE885, a BCMA-directed CAR-T cells, manufactured with a new process. CAR-T cells will be investigated as a single
- Study number:
- NCT05172596
- Cohorts:
- 1
- Study phase:
- 2
- Overall status:
- Recruiting
- Study type:
- Targeted therapy
Novartis
Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2
The purpose of this study is to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-lin
- Study number:
- NCT04935359
- Cohorts:
- 2
- Study phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Targeted therapy, Chemotherapy
Novartis
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC
The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with
- Study number:
- NCT04720157
- Cohorts:
- 1
- Study phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Local/Regional therapies, Chemotherapy
Novartis
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study trea
- Study number:
- NCT04699188
- Cohorts:
- 1
- Study phase:
- 1, 2
- Overall status:
- Recruiting
- Study type:
- Targeted therapy, Biomarker
Novartis
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL
The purpose of the First-In-Human study is to assess safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of JBH492 as single agent.
- Study number:
- NCT04240704
- Cohorts:
- 1
- Study phase:
- 1
- Overall status:
- Recruiting
- Study type:
- Chemotherapy, Targeted therapy
Novartis
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
The purpose of this first in human (FIH) trial is to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and ide
- Study number:
- NCT03114319
- Cohorts:
- 2
- Study phase:
- 1
- Overall status:
- Recruiting
- Study type:
- Targeted therapy, Biomarker